Targeting a systolic blood pressure (SBP) below 130 mmHg may significantly reduce hospitalizations in patients with heart failure with preserved ejection fraction (HFpEF), a recent systematic review ...

Scientists from the University of Electronic Science and Technology of China have developed a smart contact lens that can ...

Persistent high blood pressure, or resistant hypertension, requires a proactive and personalized approach beyond just ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

US biopharma Mineralys Therapeutics has announced positive topline data from its Phase II Explore-CKD trial evaluating the ...

Presentation underscores unique potential for atrioventricular interval modulation (“AVIM”) therapy to manage blood pressure in older, high-risk patients who have indicators of diastolic dysfunction ...

Do you want to know how strong your heart is? Knowing this is very important because the heart is the most important organ in ...

We often see heart attacks as sudden, dramatic events, often depicted on television. It shows someone clutching their chest, ...

The latest clinical win follows a dual set of phase 3 and phase 2 results back in March. In that data drop, Mineralys reported that lorundrostat reduced systolic blood pressure in a late-stage study ...

A concerning trend has emerged in cardiovascular health awareness among American adults, according to new research published in JAMA Cardiology. The study reveals that hypertension awareness has ...

Emphysema subtypes, identified via CT, may be linked to cardiopulmonary subphenotypes that can help to target cardiac care in early COPD.

Investing.com -- Mineralys Therapeutics Inc (NASDAQ: MLYS) stock surged 7.9% after reporting positive topline data from its Phase 2 Explore-CKD trial for lorundrostat in patients with hypertension and ...